Drug Profile


Alternative Names: DS 5565

Latest Information Update: 13 Jul 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Acetic acids; Analgesics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuropathic pain; Pain; Postherpetic neuralgia

Most Recent Events

  • 25 May 2017 Daiichi Sankyo completes a phase III trial in Postherpetic neuralgia in Japan, Philippines, Malaysia, Singapore, South Korea, Taiwan, Thailand (PO) (NCT02318719)
  • 01 Mar 2017 Daiichi Sankyo completes a phase III trial for Postherpetic neuralgia and Neuropathic pain (in patients with diabetic peripheral neuropathy and renal impairment) in Japan (PO) (NCT02607280)
  • 12 Jan 2017 Daiichi Sankyo completes a phase III trial for Pain associated with fibromyalgia in USA, Austria, Argentina, Belarus, Belgium, Chile, Colombia, Israel, Mexico, Poland, Portugal, Slovenia, Spain, Switzerland (NCT02187471)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top